Detection of Trop2 levels and immune response against Trop2 protein in ovarian cancer patients
- Conditions
- Health Condition 1: C569- Malignant neoplasm of unspecifiedovary
- Registration Number
- CTRI/2019/02/017408
- Lead Sponsor
- ICMR National Institute for Research in Reproductive Health
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Group A - Women with epithelial ovarian carcinoma as determined by histopathology/cytology aged 18-75 years
2.Group B - Age-matched healthy women with no reported symptoms gynecological problem (e.g. Ovarian cysts, uterine fibroids, RTI etc.)
3.Group C- Women with cervical disorder with morphologically normal ovaries undergoing hysterectomy along with oophorectomy
1.Group A- Non-epithelial ovarian carcinoma patients, Ovarian carcinoma patient coming with a recurrence, Patients with secondary ovarian carcinoma. Retrovirus infected patients and patients taking steroids for other disorders.
2.Group C- Cystic ovaries or ovaries with benign growth or any other significant abnormality, women with uterine endometrial disorders. Women with autoimmune disorder
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method â??To qualitatively and quantitatively measure the presence of Trop2 protein in ovarian tissue and serum of patients with epithelial ovarian cancer and healthy participantsTimepoint: Since its an observational study the time point is the first patient contact. We are not calculating statistical variables related to followup.
- Secondary Outcome Measures
Name Time Method To study the presence of autoantibodies and Trop2 reactive T-cells in serum of patients with ovarian cancer and healthy participantsTimepoint: Since its an observational study the time point is the first patient contact. We are not calculating statistical variables related to followup.